MA46942A - Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1) - Google Patents
Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1)Info
- Publication number
- MA46942A MA46942A MA046942A MA46942A MA46942A MA 46942 A MA46942 A MA 46942A MA 046942 A MA046942 A MA 046942A MA 46942 A MA46942 A MA 46942A MA 46942 A MA46942 A MA 46942A
- Authority
- MA
- Morocco
- Prior art keywords
- hpk1
- anilinopyrimidines
- kinase
- inhibitors
- hematopoietic progenitors
- Prior art date
Links
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000008059 anilinopyrimidines Chemical class 0.000 title 1
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428191P | 2016-11-30 | 2016-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46942A true MA46942A (fr) | 2021-05-05 |
Family
ID=60629854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046942A MA46942A (fr) | 2016-11-30 | 2017-11-29 | Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11180482B2 (OSRAM) |
| EP (1) | EP3548479A1 (OSRAM) |
| JP (1) | JP7025426B2 (OSRAM) |
| MA (1) | MA46942A (OSRAM) |
| WO (1) | WO2018102366A1 (OSRAM) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA48994A (fr) | 2017-03-30 | 2020-02-05 | Hoffmann La Roche | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 |
| JP7167146B2 (ja) | 2017-11-06 | 2022-11-08 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｐｋ１阻害剤として有用なイソフラノン化合物 |
| TW202012405A (zh) * | 2018-07-24 | 2020-04-01 | 瑞士商赫孚孟拉羅股份公司 | 萘啶化合物及其用途 |
| EP3826722A1 (en) | 2018-07-24 | 2021-06-02 | F. Hoffmann-La Roche AG | Isoquinoline compounds and uses thereof |
| JP7433304B2 (ja) * | 2018-09-30 | 2024-02-19 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | シンノリン化合物および癌などのｈｐｋ１依存性障害の治療 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| US11071730B2 (en) * | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020120257A1 (en) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US12492194B2 (en) | 2019-03-26 | 2025-12-09 | Janssen Pharmaceutica Nv | HPK1 inhibitors |
| MA55478A (fr) | 2019-03-26 | 2022-02-09 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques de hpk1 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| NZ783169A (en) | 2019-06-25 | 2024-12-20 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| MA56462A (fr) * | 2019-07-04 | 2022-05-11 | Qilu Regor Therapeutics Inc | Inhibiteurs de hpk1 et leurs utilisations |
| WO2021004535A1 (en) * | 2019-07-11 | 2021-01-14 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Cinnolines as inhibitors of hpk 1 |
| CN110428982B (zh) * | 2019-07-31 | 2021-03-02 | 太仓碧奇新材料研发有限公司 | 一种超级电容器隔膜的制备方法 |
| BR112022004451A2 (pt) * | 2019-09-13 | 2022-06-21 | Nimbus Saturn Inc | Antagonistas de hpk1 e usos dos mesmos |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US20240270698A2 (en) * | 2019-12-16 | 2024-08-15 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative and use thereof |
| EP4079726A4 (en) * | 2019-12-16 | 2024-01-24 | Korea Research Institute of Chemical Technology | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| JP2023510918A (ja) * | 2020-01-15 | 2023-03-15 | ブループリント メディシンズ コーポレイション | Ｍａｐ４ｋ１阻害剤 |
| WO2021163629A1 (en) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Inhibitors of ulk1/2 and methods of using same |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| JP2023522863A (ja) * | 2020-04-14 | 2023-06-01 | 斉魯制薬有限公司 | Ｅｇｆｒ阻害剤としての三環式化合物 |
| WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| WO2021239133A1 (zh) * | 2020-05-29 | 2021-12-02 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| CN116456985A (zh) * | 2020-09-23 | 2023-07-18 | 深圳市原力生命科学有限公司 | 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法 |
| CN114437074A (zh) | 2020-11-03 | 2022-05-06 | 北京伯汇生物技术有限公司 | 一种化合物、含该化合物的药物组合物及其用途 |
| US20230416225A1 (en) * | 2020-11-09 | 2023-12-28 | Merck Sharp & Dohme Llc | Diaminopyrimidine carboxamide inhibitors of hpk1 |
| WO2022100688A1 (zh) * | 2020-11-13 | 2022-05-19 | 南京红云生物科技有限公司 | Hpk1激酶调节剂、其制备方法与应用 |
| WO2022111517A1 (zh) * | 2020-11-24 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 氘修饰的噻吩并吡啶酮化合物 |
| CN114805330A (zh) * | 2021-01-22 | 2022-07-29 | 苏州信诺维医药科技股份有限公司 | Hpk1抑制剂、其制备方法、药物组合物及其应用 |
| WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| JP2024510176A (ja) * | 2021-03-08 | 2024-03-06 | ブループリント メディシンズ コーポレイション | Ｍａｐ４ｋ１阻害剤 |
| CN117295748A (zh) * | 2021-03-08 | 2023-12-26 | 缆图药品公司 | Map4k1抑制剂 |
| WO2022199589A1 (zh) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶衍生物 |
| TW202246263A (zh) * | 2021-03-23 | 2022-12-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Ｈｐｋ１激酶抑制劑化合物 |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| WO2022214008A1 (zh) * | 2021-04-08 | 2022-10-13 | 杭州阿诺生物医药科技有限公司 | 高活性hpk1激酶抑制剂 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| PE20240585A1 (es) * | 2021-07-06 | 2024-03-21 | Glenmark Specialty Sa | Compuestos pirimidinicos para usar como inhibidores de map4k1 |
| US12202844B2 (en) | 2021-07-14 | 2025-01-21 | Blueprint Medicines Corporation | MAP4K1 inhibitors |
| JP2024527623A (ja) | 2021-07-20 | 2024-07-25 | アストラゼネカ・アクチエボラーグ | 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 |
| CN115838373A (zh) | 2021-09-18 | 2023-03-24 | 北京伯汇生物技术有限公司 | 氮杂吲唑大环化合物及其用途 |
| CN115838383A (zh) * | 2021-09-22 | 2023-03-24 | 南京正大天晴制药有限公司 | 作为axl抑制剂的苯并环庚烷类化合物 |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN116178433A (zh) * | 2021-11-26 | 2023-05-30 | 南京正大天晴制药有限公司 | Axl激酶抑制剂的盐及其制备方法和用途 |
| CN116178434A (zh) * | 2021-11-26 | 2023-05-30 | 南京正大天晴制药有限公司 | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024545193A (ja) | 2021-12-22 | 2024-12-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118184669B (zh) * | 2023-03-17 | 2025-09-23 | 北京伯汇生物技术有限公司 | 作为多靶点激酶抑制剂的大环化合物 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20250041906A (ko) * | 2023-09-19 | 2025-03-26 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| AU2009248923B2 (en) | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| JP2013539795A (ja) | 2010-10-14 | 2013-10-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖の阻害方法 |
| WO2015038868A1 (en) | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US10053458B2 (en) * | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
-
2017
- 2017-11-29 WO PCT/US2017/063633 patent/WO2018102366A1/en not_active Ceased
- 2017-11-29 JP JP2019528807A patent/JP7025426B2/ja active Active
- 2017-11-29 US US16/465,073 patent/US11180482B2/en active Active
- 2017-11-29 MA MA046942A patent/MA46942A/fr unknown
- 2017-11-29 EP EP17811814.7A patent/EP3548479A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20190382379A1 (en) | 2019-12-19 |
| WO2018102366A1 (en) | 2018-06-07 |
| US11180482B2 (en) | 2021-11-23 |
| EP3548479A1 (en) | 2019-10-09 |
| JP2020503271A (ja) | 2020-01-30 |
| JP7025426B2 (ja) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46942A (fr) | Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1) | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| BR112017006137A2 (pt) | formulação que contém biotensoativo | |
| EP3138842A4 (en) | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| EP3386981A4 (en) | HETEROCYCLES SUITABLE AS ANTICROGEN | |
| MA53110A (fr) | Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton | |
| EP3247970A4 (en) | Single aperture laser range finder | |
| MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| HUE040304T2 (hu) | 2-Amino-6-(difluor-metil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridinek, mint bace1 inhibitorok | |
| EP3328840A4 (en) | SUBSTITUTED BICYCLIC TRIAZOL COMPOUNDS AS PDE2 INHIBITORS | |
| EP3102571A4 (en) | EGFR-T790M KINASEINHIBITORS USEFUL SUBSTITUTED PYRIMIDINES | |
| MA41542A (fr) | Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase | |
| ZA201804944B (en) | Stable liquid gonadotropin formulation | |
| MA46615A (fr) | Inhibiteurs de nav1.7 de type acyl-sulfonamide | |
| HUE053428T2 (hu) | Eljárás otikus progenitorok elõállítására | |
| EP3452477C0 (en) | Adenine derivatives as protein kinase inhibitors | |
| EP4293116A3 (fr) | Fibrinogène liquide stable | |
| EP2976338A4 (en) | N- (2-CYANO-HETEROCYCLYL) PYRAZOLPYRIDONE AS JANUSKINASEINHIBITORS | |
| EP3321713A4 (en) | LASER RANGEFINDER |